Sort:
Open Access Correspondence Issue
Targeting homologous recombination repair to potentiate fluoroquinolone efficacy in Mycobacterium abscessus
mLife 2026, 5(5): 670-674
Published: 22 September 2026
Abstract PDF (840.1 KB) Collect
Downloads:0
Open Access Original Research Issue
A CRISPR‐nonhomologous end‐joining‐based strategy for rapid and efficient gene disruption in Mycobacterium abscessus
mLife 2025, 4(2): 169-180
Published: 23 April 2025
Abstract PDF (2.1 MB) Collect
Downloads:25

Mycobacterium abscessus, a fast‐growing, non‐tuberculous mycobacterium resistant to most antimicrobial drugs, causes a wide range of serious infections in humans, posing a significant public health challenge. The development of effective genetic manipulation tools for M. abscessus is still in progress, limiting both research and therapeutic advancements. However, the clustered regularly interspaced short palindromic repeats (CRISPR)‐associated protein (Cas) systems have emerged as promising tools for generating highly specific double‐strand breaks (DSBs) in its genome. One of the mechanisms that repair these DSBs is the error‐prone nonhomologous end‐joining (NHEJ) pathway, which facilitates targeted gene editing. In this study, we introduced a novel application of the CRISPR‐NHEJ approach in M. abscessus. We demonstrated that NrgA from M. marinum plays a crucial role in repairing DSBs induced by the CRISPR‐Cas system in M. abscessus. Contrary to previous findings, our study also revealed that inhibiting or overexpressing components of homologous recombination/single‐strand annealing significantly reduces the efficiency of NHEJ repair in M. abscessus. This discovery challenges current perspectives and suggests that NHEJ repair in M. abscessus may involve components from both homologous recombination and single‐strand annealing pathways, highlighting the complex interactions among the three DSB repair mechanisms in M. abscessus.

Open Access Original Research Issue
EmbB and EmbC regulate the sensitivity of Mycobacterium abscessus to echinomycin
mLife 2024, 3(3): 459-470
Published: 30 September 2024
Abstract PDF (2.1 MB) Collect
Downloads:4

Treatment of Mycobacterium abscessus (Mab) infections is very challenging due to its intrinsic resistance to most available drugs. Therefore, it is crucial to discover novel anti-Mab drugs. In this study, we explored an intrinsic resistance mechanism through which Mab resists echinomycin (ECH). ECH showed activity against Mab at a minimum inhibitory concentration (MIC) of 2 µg/ml. A ΔembC strain in which the embC gene was knocked out showed hypersensitivity to ECH (MIC: 0.0078–0.0156 µg/ml). The MICs of ECH-resistant strains screened with reference to ΔembC ranged from 0.25 to 1 µg/ml. Mutations in EmbB, including D306A, D306N, R350G, V555I, and G581S, increased the Mab's resistance to ECH when overexpressed in ΔembC individually (MIC: 0.25–0.5 µg/ml). These EmbB mutants, edited using the CRISPR/Cpf1 system, showed heightened resistance to ECH (MIC: 0.25–0.5 µg/ml). The permeability of these Mab strains with edited genes and overexpression was reduced, as evidenced by an ethidium bromide accumulation assay, but it remained significantly higher than that of the parent Mab. In summary, our study demonstrates that ECH exerts potent anti-Mab activity and confirms that EmbB and EmbC are implicated in Mab's sensitivity to ECH. Mutation in EmbB may partially compensate for a loss of EmbC function.

Total 3